01339nas a2200169   4500000000100000008004100001260001600042653002700058653002400085653002100109100001200130245014600142300000800288490000800296520085100304022001401155       2020                            d  bElsevier BV10aMicrobiology (medical)10aInfectious Diseases10aGeneral Medicine1 aMitra D00aA randomized controlled trial of prednisolone vs TNF-alfa inhibitor Infliximab in the management of type 1 lepra reaction in leprosy patients  a4540 v1013 aLeprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae. Type 1 lepra reactions (T1R) are an acute inflammatory response during the chronic course of the disease. It is delayed hypersensitivity (type IV) reaction which if not treated promptly with immune suppression, can lead to permanent disability affecting hands, feet and eyes. Tumour necrosis factor-alpha (TNF-α) is up regulated in patients of type I lepra reaction. Conventionally oral corticosteroids steroids have been the main stay in the management of type 1 lepra reactions. We report the results of this randomized control study wherein an immuno-modulator biologic molecule (Infliximab) has been safely used to treat an inflammatory reaction. Outcomes were measured using recurrence rate, a clinical severity score, quality of life and adverse events.  a1201-9712